PubRank

Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 24672742)

Published in J Clin Cell Immunol on December 01, 2013

Authors

José A Gómez-Puerta1, Sushrut S Waikar2, Daniel H Solomon3, Jun Liu4, Graciela S Alarcón5, Wolfgang C Winkelmayer6, Karen H Costenbader1

Author Affiliations

1: Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
2: Division of Nephrology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
3: Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA ; Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
4: Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
5: Division of Rheumatology and Clinical Immunology, University of Alabama at Birmingham, Birmingham, AL, USA.
6: Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA, USA.

Articles cited by this ↗

Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13

Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int (1997) 2.25

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21

Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis (1999) 2.03

Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.93

Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken) (2011) 1.57

Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum (2005) 1.41

An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis (2010) 1.20

Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med (1982) 1.05

Associations of race and ethnicity with anemia management among patients initiating renal replacement therapy. J Natl Med Assoc (2007) 0.94

National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis (1993) 0.88

Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report. J Rehabil Res Dev (2010) 0.84

What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation (2011) 0.83